Recently Published Trials Results
- SUBTYPE OF MDS: Chronic myelomonocytc leukaemia (CMML)
- SEVERITY OF MDS: CMML specific prognostic score (CPSS) Intermediate-2 or high risk
- NAME OF DRUG: Tefinostat, a histone deacetylase inhibitor that targets monocytes. Tefinostat will be administered orally on a continuous basis for at least 6 cycles each 28 days in length.
- SUB-TYPE OF MDS: IPSS-R and ring sideroblasts
- SEVERITY OF MDS: Low or Intermediate
- NAME OF DRUG: Luspatercept, a protein found to promote red blood cell formation by regulating the growth of red blood cells during the late-stage of their development. It works differently to erythropoietin.